Results 61 to 70 of about 22,675 (238)
Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He +11 more
wiley +1 more source
, 2021 The anti-CD20 monoclonal antibody rituximab is a revolution in the treatment of pemphigus, a rare and chronic relapsing autoimmune blistering disease. Complete remission off-therapy became an attainable goal with rituximab.
Meijer, J. M.; id_orcid +3 more
core +3 more sources
Pemphigus: use of the Japanese severity index in 56 Moroccan patients
The Pan African Medical Journal, 2013 INTRODUCTION: In pemphigus, there still is no consensus on parameters mesuring clinically the disease severity. The aim of this study is to use the Japanese severity index in Moroccan patients with pemphigus.
Hakima Benchikhi +4 more
doaj +1 more source
Anais Brasileiros de Dermatologia, 2011 FUNDAMENTO: Há dois tipos principais de pênfigo: pênfigo vulgar e pênfigo foliáceo. Nos últimos anos, mudanças clínicas e epidemiológicas relacionadas aos pênfigos têm sido observadas.
Gilson Antonio Pereira Gonçalves +5 more
doaj +1 more source
Diagnostic difficulties in a case of a female patient with pemphigus vulgaris
, 2016 Introduction . Autoimmune blistering diseases are mediated by autoantibodies directed against structural proteins of the skin. Pemphigus vulgaris (PV) is the most common type of pemphigus.
Kamila Zawadzińska-Halat +4 more
core +1 more source
Cyclophosphamide is associated with long‐term treatment‐free remission in patients with pemphigus
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and objective Pemphigus treatment has seen significant advancements, yet long‐term remission remains a challenge. Comparative data on the long‐term effectiveness of available therapies are limited. We compared 10‐year relapse rates in pemphigus patients treated with azathioprine or cyclophosphamide plus high‐dose IV corticosteroids ...
Bettina Santler +5 more
wiley +1 more source
Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic
Biomedicines, 2021 Pemphigus is a rare autoimmune disease characterised by the production of pathogenic autoantibodies in response to different desmosome proteins. The pathophysiological process leads to the development of blisters and erosions on mucosal and/or skin ...
Branka Marinović +3 more
doaj +1 more source
European Journal of Dental Education, EarlyView.ABSTRACT Aim To compare the item difficulty and discriminative index of multiple‐choice questions (MCQs) generated by ChatGPT with those created by dental educators, based on the performance of dental students in a real exam setting. Materials and Methods A total of 40 MCQs—20 generated by ChatGPT 4.0 and 20 by dental educators—were developed based on ...
Nezaket Ezgi Özer +4 more
wiley +1 more source
Development of a Desmocollin-3 Active Mouse Model Recapitulating Human Atypical Pemphigus
Frontiers in Immunology, 2019 Pemphigus vulgaris (PV) is a life-threatening mucocutaneous autoimmune blistering disease. It is often associated with autoantibodies to the desmosomal adhesion proteins Desmoglein 3 (DSG3) and Desmoglein 1 (DSG1).
Roberta Lotti +6 more
doaj +1 more source
Utility of IgG4 immunohistochemistry detection in pemphigus diagnosis
SAGE Open Medical Case Reports, 2022 Pemphigus includes a group of blistering autoimmune diseases that affect the skin and mucosa, characterized by the formation of epidermal bullous and the presence of antibodies against binding proteins.
Maricela García-Lechuga +4 more
doaj +1 more source